Skip to main content
Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQ: ARQT · IEX Real-Time Price · USD
9.30
-0.26 (-2.72%)
At close: Jul 2, 2024, 4:00 PM
9.35
+0.05 (0.54%)
After-hours: Jul 2, 2024, 7:59 PM EDT

Arcutis Biotherapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year
 20232022202120202019 2018 - 2017
Revenue
59.613.69000
Upgrade
Revenue Growth (YoY)
1517.09%----
Upgrade
Cost of Revenue
4.990.75000
Upgrade
Gross Profit
54.622.93000
Upgrade
Selling, General & Admin
185.15122.1260.9721.346.61
Upgrade
Research & Development
110.58182.44145.56115.3136.52
Upgrade
Operating Expenses
295.72304.56206.53136.6543.13
Upgrade
Operating Income
-241.1-301.63-206.53-136.65-43.13
Upgrade
Interest Expense / Income
29.7115.65000
Upgrade
Other Expense / Income
-11.79-5.82-0.17-0.97-1.14
Upgrade
Pretax Income
-259.03-311.46-206.36-135.68-42
Upgrade
Income Tax
3.110000
Upgrade
Net Income
-262.14-311.46-206.36-135.68-42
Upgrade
Shares Outstanding (Basic)
695549362
Upgrade
Shares Outstanding (Diluted)
695549362
Upgrade
Shares Change
25.94%11.39%38.51%1835.11%48.68%
Upgrade
EPS (Basic)
-3.78-5.66-4.18-3.80-22.78
Upgrade
EPS (Diluted)
-3.78-5.66-4.18-3.80-22.78
Upgrade
Free Cash Flow
-247.49-258.05-175.62-113.35-43.13
Upgrade
Free Cash Flow Per Share
-3.57-4.69-3.56-3.18-23.40
Upgrade
Gross Margin
91.63%79.54%---
Upgrade
Operating Margin
-404.49%-8183.04%---
Upgrade
Profit Margin
-439.79%-8449.76%---
Upgrade
Free Cash Flow Margin
-415.20%-7000.76%---
Upgrade
EBITDA
-227.43-294.55-205.59-135.22-41.8
Upgrade
EBITDA Margin
-381.56%-7991.13%---
Upgrade
Depreciation & Amortization
1.881.250.760.460.2
Upgrade
EBIT
-229.32-295.81-206.36-135.68-42
Upgrade
EBIT Margin
-384.72%-8025.12%---
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).